MedTrace Logo

Vaccine Therapy in Treating Patients With Metastatic Melanoma of the Eye

NCT00020475 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2024-03-04

No results posted yet for this study

Summary

RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Combining vaccine therapy with interleukin-2 may be a more effective treatment for metastatic melanoma of the eye.

PURPOSE: Phase II trial to study the effectiveness of vaccine therapy and interleukin-2 in treating patients who have metastatic melanoma of the eye.

Conditions

  • Extraocular Extension Melanoma
  • Recurrent Intraocular Melanoma

Interventions

DRUG

gp100 antigen

DRUG

interleukin-2

DRUG

MART-1 antigen

DRUG

Montanide ISA-51

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    lead NIH

Principal Investigators

  • Francesco M. Marincola · National Cancer Institute (NCI)

Study Design

Purpose
TREATMENT

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-02-28
Completion
2007-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00020475 on ClinicalTrials.gov